Association Between Peak Serum Bilirubin and Neurodevelopmental Outcomes in Extremely Low Birth Weight Infants
* Women and Infants’ Hospital of Rhode Island/Brown University, Providence, Rhode Island
University of Texas-Houston, Houston, Texas
Case Western Reserve University, Cleveland, Ohio
|| University of Alabama at Birmingham, Birmingham, Alabama
¶ Research Triangle Institute; Research Triangle Park, North Carolina
# Emory University, Atlanta, Georgia
** Wayne State University, Detroit, Michigan
Yale University, New Haven, Connecticut
National Institute of Child Health and Human Development, Rockville, Maryland
Objective. To assess the association between peak total serum bilirubin (PSB) levels during the first 2 weeks of life and neurodevelopmental outcomes of extremely low birth weight (ELBW) infants at 18 to 22 months’ postmenstrual age.
Methods. A retrospective analysis was conducted of a cohort of ELBW infants (401–1000 g) who survived to 14 days of age in the 12 participating centers of the National Institute of Child Health and Human Development Neonatal Research Network between January 1, 1994, and December 31, 1997. Demographic and clinical risk factors and PSB levels during the first 14 days were analyzed with reference to death or adverse neurodevelopmental outcomes at 18 to 22 months’ postmenstrual age. The neurodevelopmental variables considered were Psychomotor Developmental Index (PDI) <70, Mental Developmental Index (MDI) <70, moderate or severe cerebral palsy (CP), hearing impairment (needs hearing aids), and a composite category designated as neurodevelopmental impairment (NDI). The NDI is defined as infants with any 1 or more of the following: PDI <70, MDI <70, moderate to severe CP, bilateral blindness, or bilateral hearing impairment requiring amplification.
Results. The subjects of this cohort analysis are infants who were admitted to the Network centers during calendar years 1994–1997 and survived beyond 14 days and had PSB recorded during the 14-day period. From this cohort, 3246 infants survived at discharge, 79 died after discharge, and 592 were lost to follow-up. Thus, 2575 of 3167 infants were seen in the follow-up clinics with a compliance rate of 81%. Logistic regression analysis showed that various demographic and clinical variables are associated with poor neurodevelopmental outcomes. After adjustment for these risk factor, significant association were found between PSB (mg/dL) and death or NDI (odds ratio: 1.068; 95% confidence interval [CI]: 1.03–1.11); PDI <70 (R = 1.057; 95% CI: 1.00–1.12), and hearing impairment requiring hearing aids (odds ratio: 1138; 95% CI: 1.00–1.30). There was no significant association between PSB (mg/dL) and CP, MDI <70, and NDI.
Conclusions. PSB concentrations during the first 2 weeks of life are directly correlated with death or NDI, hearing impairment, and PDI <70 in ELBW infants. The statistical association based on retrospective analysis of observational data and relatively small effect size should be interpreted with caution. Furthermore, because of the possibility of compounding effects of variables on outcome, the potential benefits of moderate hyperbilirubinemia and the potential adverse effects of phototherapy, a randomized, controlled trial of aggressive and conservative phototherapy is needed to address this controversial issue.
Key Words: serum bilirubin • hyperbilirubinemia • extremely low birth weight infant • neurodevelopmental outcome
Abbreviations: BBCA, bilirubin binding capacity of albumin • ELBW, extremely low birth weight • PSB, peak serum bilirubin • GDB, generic database • CP, cerebral palsy • MDI, Mental Developmental Index • PDI, Psychomotor Developmental Index • NDI, neurodevelopmental impairment • IVH, intraventricular hemorrhage • CLD, chronic lung disease • PVL, periventricular leukomalacia • NEC, necrotizing enterocolitis • CI, confidence interval • OR, odds ratio
Received for publication Feb 21, 2003; Accepted Jun 4, 2003.
CiteULike 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  E. Zecca, C. Romagnoli, M. P. De Carolis, S. Costa, R. Marra, and D. De Luca Does Ibuprofen Increase Neonatal Hyperbilirubinemia? Pediatrics, August 1, 2009; 124(2): 480 - 484. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Ahlfors, R. P. Wennberg, J. D. Ostrow, and C. Tiribelli Unbound (Free) Bilirubin: Improving the Paradigm for Evaluating Neonatal Jaundice Clin. Chem., July 1, 2009; 55(7): 1288 - 1299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. B. Amin, D. Prinzing, and G. Myers Hyperbilirubinemia and Language Delay in Premature Infants Pediatrics, January 1, 2009; 123(1): 327 - 331. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. H. Morris, W. Oh, J. E. Tyson, D. K. Stevenson, D. L. Phelps, T. M. O'Shea, G. E. McDavid, R. L. Perritt, K. P. Van Meurs, B. R. Vohr, et al. Aggressive vs. Conservative Phototherapy for Infants with Extremely Low Birth Weight N. Engl. J. Med., October 30, 2008; 359(18): 1885 - 1896. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Murakami, M. Morimoto, K. Yamada, O. Kizu, A. Nishimura, T. Nishimura, and T. Sugimoto Fiber-Tracking Techniques Can Predict the Degree of Neurologic Impairment for Periventricular Leukomalacia Pediatrics, September 1, 2008; 122(3): 500 - 506. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C V Hulzebos, D E van Imhoff, A F Bos, C E Ahlfors, H J Verkade, and P H Dijk Usefulness of the bilirubin/albumin ratio for predicting bilirubin-induced neurotoxicity in premature infants Arch. Dis. Child. Fetal Neonatal Ed., September 1, 2008; 93(5): F384 - F388. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Bender, W. J. Cashore, and W. Oh Ontogeny of Bilirubin-Binding Capacity and the Effect of Clinical Status in Premature Infants Born at Less Than 1300 Grams Pediatrics, November 1, 2007; 120(5): 1067 - 1073. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Schulzke, G. C. Deshpande, and S. K. Patole Neurodevelopmental Outcomes of Very Low-Birth-Weight Infants With Necrotizing Enterocolitis: A Systematic Review of Observational Studies Arch Pediatr Adolesc Med, June 1, 2007; 161(6): 583 - 590. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Wennberg, C. E. Ahlfors, V. K. Bhutani, L. H. Johnson, and S. M. Shapiro Toward Understanding Kernicterus: A Challenge to Improve the Management of Jaundiced Newborns Pediatrics, February 1, 2006; 117(2): 474 - 485. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. F. McDonagh and M. J. Maisels Bilirubin Unbound: Deja Vu All Over Again? Pediatrics, February 1, 2006; 117(2): 523 - 525. [Full Text] [PDF]
|
|
|
|
|
|
S. L. Merhar and D. L. Gilbert Clinical (Video) Findings and Cerebrospinal Fluid Neurotransmitters in 2 Children With Severe Chronic Bilirubin Encephalopathy, Including a Former Preterm Infant Without Marked Hyperbilirubinemia Pediatrics, November 1, 2005; 116(5): 1226 - 1230. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Meadow, W. Oh, B. R. Vohr, J. E. Tyson, A. A. Fanaroff, B. J. Stoll, R. A. Ehrenkranz, W. Carlo, S. Shankaran, K. Poole, et al. Importance of Bilirubin Effect Questioned Pediatrics, March 1, 2004; 113(3): 627 - 628. [Full Text] [PDF]
|
|
